Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has announced it will release its third quarter 2024 financial results on November 4, 2024 after US market close. The company will host an investor conference call and webcast on November 5, 2024 at 8:00 AM ET / 2:00 PM CET to discuss the quarterly results and provide a business update.
Cellectis (NASDAQ: CLLS), una compagnia di biotecnologie in fase clinica focalizzata sulla modifica genetica e le terapie cellulari, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 il 4 novembre 2024 dopo la chiusura del mercato statunitense. L'azienda terrà una conferenza telefonica per investitori e un webcast il 5 novembre 2024 alle 8:00 AM ET / 2:00 PM CET per discutere i risultati trimestrali e fornire un aggiornamento sulle attività.
Cellectis (NASDAQ: CLLS), una empresa de biotecnología en etapa clínica centrada en la edición genética y las terapias celulares, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el 4 de noviembre de 2024 después del cierre del mercado estadounidense. La compañía llevará a cabo una llamada de conferencia para inversores y un webcast el 5 de noviembre de 2024 a las 8:00 AM ET / 2:00 PM CET para discutir los resultados trimestrales y proporcionar una actualización del negocio.
Cellectis (NASDAQ: CLLS)는 유전자 편집 및 세포 요법에 초점을 맞춘 임상 단계 생명공학 회사로, 2024년 3분기 재무 결과를 2024년 11월 4일 미국 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 2024년 11월 5일 오전 8시 ET / 오후 2시 CET에 투자자 컨퍼런스 콜과 웹캐스트를 열어 분기별 결과를 논의하고 비즈니스 업데이트를 제공할 예정입니다.
Cellectis (NASDAQ: CLLS), une entreprise de biotechnologie en phase clinique spécialisée dans l'édition génétique et les thérapies cellulaires, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024 après la fermeture du marché américain. L'entreprise organisera un appel de conférence pour les investisseurs et un webinaire le 5 novembre 2024 à 8h00 HE / 14h00 CET pour discuter des résultats trimestriels et fournir des mises à jour sur les affaires.
Cellectis (NASDAQ: CLLS), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Gen-Editing und Zelltherapien spezialisiert hat, hat bekannt gegeben, dass es seine Finanzergebnisse für das dritte Quartal 2024 am 4. November 2024 nach dem US-Marktschluss veröffentlichen wird. Das Unternehmen wird am 5. November 2024 um 8:00 Uhr ET / 14:00 Uhr MEZ eine Telefonkonferenz für Investoren und ein Webcast abhalten, um die Quartalszahlen zu besprechen und ein Update zum Geschäft zu geben.
- None.
- None.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market.
The publication will be followed by an investor conference call and webcast on Tuesday, November 5, 2024 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s third quarter results and an update on business activities. Details for the call are as follows:
Dial in information:
Domestic: +1-800-225-9448
International: +1-203-518-9708
Conference ID: CLLSQ3
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1688144&tp_key=affca25222
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit our website: www.cellectis.com
Follow Cellectis on social networks @cellectis on LinkedIn and X (formerly Twitter)
TALEN® is a registered trademark owned by Cellectis.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Attachment
FAQ
When will Cellectis (CLLS) report Q3 2024 earnings?
When is Cellectis (CLLS) Q3 2024 earnings call?